| |  Online-Ressource |
|---|
| Verfasst von: | Nowatzke, Joseph [VerfasserIn]  |
|---|
| | Guedeney, Paul [VerfasserIn] |
|---|
| | Palaskas, Nicholas [VerfasserIn] |
|---|
| | Lehmann, Lorenz [VerfasserIn] |
|---|
| | Ederhy, Stephane [VerfasserIn] |
|---|
| | Zhu, Han [VerfasserIn] |
|---|
| | Cautela, Jennifer [VerfasserIn] |
|---|
| | Francis, Sanjeev [VerfasserIn] |
|---|
| | Courand, Pierre-Yves [VerfasserIn] |
|---|
| | Deswal, Anita [VerfasserIn] |
|---|
| | Ewer, Steven M. [VerfasserIn] |
|---|
| | Aras, Mandar [VerfasserIn] |
|---|
| | Arangalage, Dimitri [VerfasserIn] |
|---|
| | Ghafourian, Kambiz [VerfasserIn] |
|---|
| | Fenioux, Charlotte [VerfasserIn] |
|---|
| | Finke, Daniel [VerfasserIn] |
|---|
| | Peretto, Giovanni [VerfasserIn] |
|---|
| | Zaha, Vlad [VerfasserIn] |
|---|
| | Itzhaki Ben Zadok, Osnat [VerfasserIn] |
|---|
| | Tajiri, Kazuko [VerfasserIn] |
|---|
| | Akhter, Nausheen [VerfasserIn] |
|---|
| | Levenson, Joshua [VerfasserIn] |
|---|
| | Baldassarre, Lauren [VerfasserIn] |
|---|
| | Power, John [VerfasserIn] |
|---|
| | Huang, Shi [VerfasserIn] |
|---|
| | Collet, Jean-Philippe [VerfasserIn] |
|---|
| | Moslehi, Javid [VerfasserIn] |
|---|
| | Salem, Joe-Elie [VerfasserIn] |
|---|
| Titel: | Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis |
|---|
| Titelzusatz: | report from an international registry |
|---|
| Verf.angabe: | Joseph Nowatzke, Paul Guedeney, Nicholas Palaskas, Lorenz Lehmann, Stephane Ederhy, Han Zhu, Jennifer Cautela, Sanjeev Francis, Pierre-Yves Courand, Anita Deswal, Steven M. Ewer, Mandar Aras, Dimitri Arangalage, Kambiz Ghafourian, Charlotte Fenioux, Daniel Finke, Giovanni Peretto, Vlad Zaha, Osnat Itzhaki Ben Zadok, Kazuko Tajiri, Nausheen Akhter, Joshua Levenson, Lauren Baldassarre, John Power, Shi Huang, Jean-Philippe Collet, Javid Moslehi, Joe-Elie Salem, International ICI-myocarditis registry contributors Nazanin Aghel, Joachim Alexandre, Kazutaka Aonuma [und weitere] |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 26 November 2022 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Gesehen am 25.01.2024 |
|---|
| Titel Quelle: | Enthalten in: European journal of cancer |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1992 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 177(2022) vom: Dez., Seite 197-205 |
|---|
| ISSN Quelle: | 1879-0852 |
|---|
| Abstract: | Purpose - Immune checkpoint blocker (ICB) associated myocarditis (ICB-myocarditis) may present similarly and/or overlap with other cardiac pathology including acute coronary syndrome presenting a challenge for prompt clinical diagnosis. - Methods - An international registry was used to retrospectively identify cases of ICB-myocarditis. Presence of coronary artery disease (CAD) was defined as coronary artery stenosis >70% in patients undergoing coronary angiogram. - Results - Among 261 patients with clinically suspected ICB-myocarditis who underwent a coronary angiography, CAD was present in 59/261 patients (22.6%). Coronary revascularization was performed during the index hospitalisation in 19/59 (32.2%) patients. Patients undergoing coronary revascularization less frequently received steroids administration within 24 h of admission compared to the other groups (p = 0.029). Myocarditis-related 90-day mortality was 9/17 (52.7%) in the revascularised cohort, compared to 5/31 (16.1%) in those not revascularized and 25/156 (16.0%) in those without CAD (p = 0.001). Immune-related adverse event-related 90-day mortality was 9/17 (52.7%) in the revascularized cohort, compared to 6/31 (19.4%) in those not revascularized and 31/156 (19.9%) in no CAD groups (p = 0.007). All-cause 90-day mortality was 11/17 (64.7%) in the revascularized cohort, compared to 13/31 (41.9%) in no revascularization and 60/158 (38.0%) in no CAD groups (p = 0.10). After adjustment of age and sex, coronary revascularization remained associated with ICB-myocarditis-related death at 90 days (hazard ratio [HR] = 4.03, 95% confidence interval [CI] 1.84-8.84, p < 0.001) and was marginally associated with all-cause death (HR = 1.88, 95% CI, 0.98-3.61, p = 0.057). - Conclusion - CAD may exist concomitantly with ICB-myocarditis and may portend a poorer outcome when revascularization is performed. This is potentially mediated through delayed diagnosis and treatment or more severe presentation of ICB-myocarditis. |
|---|
| DOI: | doi:10.1016/j.ejca.2022.07.018 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.ejca.2022.07.018 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S0959804922004439 |
|---|
| | DOI: https://doi.org/10.1016/j.ejca.2022.07.018 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Acute coronary syndrome |
|---|
| | Coronary revascularization |
|---|
| | Immune checkpoint blockers |
|---|
| | Immune-related adverse events |
|---|
| | Myocarditis |
|---|
| K10plus-PPN: | 1879024128 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis / Nowatzke, Joseph [VerfasserIn]; 26 November 2022 (Online-Ressource)
